Updates are available Correction dated 2018-06-13

Article History

Received: 29 September 2017

Accepted: 9 February 2018

First Online: 2 March 2018

Change Date: 13 June 2018

Change Type: Correction

Change Details: The original article contains several small errors. The errors & concurrent corrections are listed below [1]:

Ethics approval and consent to participate

: The described studies were sponsored and designed by Novartis Pharmaceuticals Corporation and were approved by the institutional review board. Patients or their guardians provided written informed consent or assent.

: Not applicable.

: DP received research support from Novartis, served on a scientific advisory board for Servier, and has a patent—CAR T cells to treat CD19+ malignancy with royalties paid by Novartis. NF received research funding from Novartis. YW is a Novartis employee. PW is a Novartis employee and stockholder. SG received grants and personal fees from Novartis and received personal fees from Jazz Pharmaceuticals and Adaptimmune.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.